- Conditions
- White Matter Injury, Brain Injury, Fetus and Neonate, Neonatal Brain Injury, Periventricular Leukomalacia, Periventricular White Matter Abnormalities
- Interventions
- Clemastine fumarate
- Drug
- Lead sponsor
- Bridget LaMonica Ostrem, M.D., Ph.D.
- Other
- Eligibility
- 3 Weeks to 20 Weeks
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 10,505
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Cystic Fibrosis
- Interventions
- N91115
- Drug
- Lead sponsor
- Nivalis Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Denver, Colorado
- Conditions
- Dyskeratosis Congenita, Telomere Biology Disorders
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Dermatitis, Atopic, Pruritus, Dermatitis Eczema
- Interventions
- ASN008 TG, Placebo TG
- Drug
- Lead sponsor
- Asana BioSciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 4
- States / cities
- Cortland, New York • High Point, North Carolina • San Antonio, Texas + 1 more
- Conditions
- Congenital Heart Defects
- Interventions
- Triostat, Placebo
- Drug
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- Up to 5 Months
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Palo Alto, California • Seattle, Washington
- Conditions
- Angelman Syndrome
- Interventions
- Alogabat
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • Boston, Massachusetts • New York, New York + 3 more
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myeloid Leukemia in Remission, Childhood Acute Myelomonocytic Leukemia (M4), Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
- Interventions
- mitoxantrone hydrochloride, cytarabine, peripheral blood stem cell transplantation, laboratory biomarker analysis
- Drug · Procedure · Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- Not listed
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Fever, Sweats, and Hot Flashes, Infection, Kidney Cancer, Leukemia, Lymphoma, Neuroblastoma, Neutropenia, Sarcoma
- Interventions
- caspofungin acetate
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years to 17 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 5
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland + 1 more
- Conditions
- Atopic Dermatitis
- Interventions
- Ruxolitinib, Vehicle Cream
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 64
- States / cities
- Birmingham, Alabama • Hoover, Alabama • Gilbert, Arizona + 49 more
- Conditions
- Bronchopulmonary Dysplasia, Neurodevelopmental Impairment
- Interventions
- SOLE, MOLE
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 12 Hours to 28 Weeks
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Autosomal Dominant Optic Atrophy, Optic Atrophy, Autosomal Dominant, Optic Atrophies, Hereditary, Kjer Optic Atrophy
- Interventions
- Not listed
- Lead sponsor
- PYC Therapeutics
- Industry
- Eligibility
- 8 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Miami, Florida • Seattle, Washington
- Conditions
- To Determine Bioequivalence Under Fed Conditions
- Interventions
- Lisinopril
- Drug
- Lead sponsor
- Par Pharmaceutical, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1999
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Spina Bifida
- Interventions
- Intervention group, Standard of care group
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 13 Years to 25 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Craniosynostosis, Philadelphia Type Craniosynostosis
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Adenovirus, Primary Immune Deficiency Disorder
- Interventions
- cytotoxic t-lymphocytes
- Drug
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- 1 Month to 79 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 10
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 6 more
- Conditions
- Pulmonary Infections, Pseudomonas Aeruginosa in Cystic Fibrosis
- Interventions
- TBM100
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Denver, Colorado • Jacksonville, Florida + 16 more
- Conditions
- Hypochondroplasia
- Interventions
- Infigratinib
- Drug
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2036
- U.S. locations
- 8
- States / cities
- Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more
- Conditions
- Tourette Syndrome, Tic Disorders, Tics
- Interventions
- Distress Tolerance Skills Training
- Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Duchenne Muscular Dystrophy, Musculoskeletal Abnormalities
- Interventions
- Not listed
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Not listed
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2031
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Arteriovenous Fistula
- Interventions
- Lutonix DCB, Standard Balloon Angioplasty Catheter, Percutaneous Transluminal Angiography
- Combination Product · Device · Procedure
- Lead sponsor
- C. R. Bard
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 20 more
- Conditions
- Blood and Lymphatic Diseases
- Interventions
- BIVV003, ST-400
- Drug
- Lead sponsor
- Sangamo Therapeutics
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2038
- U.S. locations
- 7
- States / cities
- Oakland, California • Sacramento, California • Atlanta, Georgia + 3 more
- Conditions
- Achondroplasia
- Interventions
- Recifercept
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 15 Months to 12 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 6
- States / cities
- Irvine, California • Long Beach, California • Torrance, California + 2 more
- Conditions
- Congenital Heart Defects, Dysfunctional Right Ventricular Outflow Tract Conduits
- Interventions
- Transcatheter Pulmonary Valve replacement
- Device
- Lead sponsor
- Medtronic Cardiovascular
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2020
- U.S. locations
- 5
- States / cities
- Miami, Florida • Boston, Massachusetts • New York, New York + 2 more
- Conditions
- Neurofibromatosis Type 1, Cutaneous Neurofibromas
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts